Product news from the 05/23/06 News Brief

Share this article:
The FDA approved the first generic version Forest Laboratories’ Lexapro (escitalopram oxalate) to treat major depression, according to a posting on the agency’s Web site. The decision means that Ivax Corporation of Miami, a division of Israel’s Teva Pharmaceuticals, is the first company cleared to market a generic Lexapro version in 5, 10 and 20 milligram doses.Behind Pfizer’s Zoloft, Lexapro was the number No. 2 selling antidepressant in US in 2005, according to IMS Health figures, with US sales reaching approximately $2.1 billion last year. The FDA has approved Centocor’s Remicade (infliximab) for reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients with moderately to severely active Crohn's disease (CD) who have had an inadequate response to conventional therapy. This approval establishes Remicade as the first and only biologic therapy approved for the treatment of pediatric Crohn's disease. Remicade was first approved in the US as a treatment for adult CD in 1998.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

FDA reviews new painkiller

The candidate would be the first to put oxycodone and morphine in one capsule.

AbbVie's files all-oral HCV drug with FDA

AbbVie's all-oral HCV treatment filed off six Phase-III trials spanning 25 countries and 2,300 patients

Rumor: Pfizer offered to buy AstraZeneca

The rumored $101 billion bid would give Pfizer a foothold in imuno-oncology and diabetes.